"TYK2 Kinase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is involved in signaling from a broad variety of CYTOKINE RECEPTORS. The TYK2 kinase is considered the founding member of the janus kinase family and was initially discovered as a signaling partner for the INTERFERON ALPHA-BETA RECEPTOR. The kinase has since been shown to signal from several INTERLEUKIN RECEPTORS.
| Descriptor ID |
D053634
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.650 D12.776.476.393.650
|
| Concept/Terms |
TYK2 Kinase- TYK2 Kinase
- Kinase, TYK2
- Non-Receptor Tyrosine-Protein Kinase TYK2
- Non Receptor Tyrosine Protein Kinase TYK2
- Tyrosine Kinase 2
|
Below are MeSH descriptors whose meaning is more general than "TYK2 Kinase".
Below are MeSH descriptors whose meaning is more specific than "TYK2 Kinase".
This graph shows the total number of publications written about "TYK2 Kinase" by people in this website by year, and whether "TYK2 Kinase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "TYK2 Kinase" by people in Profiles.
-
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr?Evaluation of?TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023 01; 88(1):40-51.
-
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022 06; 149(6):2010-2020.e8.
-
Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta-cell protection in type 1 diabetes. Diabetes Obes Metab. 2020 10; 22(10):1827-1836.
-
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018 10 04; 379(14):1313-1321.
-
Reduced Tyk2 gene expression in ?-cells due to natural mutation determines susceptibility to virus-induced diabetes. Nat Commun. 2015 Apr 07; 6:6748.
-
Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. Virology. 2008 Apr 25; 374(1):210-6.
-
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995 Aug; 23(9):1040-8.